Results from the FreeDM2 randomized controlled trial demonstrate that Abbott’s FreeStyle Libre continuous glucose monitoring technology significantly improves glucose outcomes compared to traditional fingerstick testing in people with Type 2 diabetes on basal insulin. The study, involving 303 participants across 24 clinical sites in the United Kingdom, found that CGM users achieved a 0.6% greater reduction in HbA1c and spent approximately 2.5 additional hours daily within healthy glucose ranges at the four-month mark.
A complementary Italian study of 88 adults on basal insulin corroborated these findings, reporting improved average glucose levels, increased time in target ranges, and enhanced quality of life after three months. Researchers attributed the improvements to participant-led self-management using real-time glucose data from FreeStyle Libre 2 and Libre 3 devices.
The results were presented at the 19th International Conference on Advanced Technologies and Treatments for Diabetes by researchers including Emma Wilmot and Lala Leelarathna of Imperial College London. Mahmood Kazemi, Chief Medical Officer of Abbott Diabetes Care, was among the key investigators involved in the research.